Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell
DOI 10.1016/j.cell.2004.11.004

Cited by (1,000)

Items 701–800 of 1,000

  1. p53: Multiple Facets of a Rubik's Cube
    Yun Zhang, Guillermina Lozano · 2016 · Annual Review of Cancer Biology
  2. A Mouse Homolog of a Human TP53 Germline Mutation Reveals a Lipolytic Activity of p53
    Ju‐Gyeong Kang, Cory U. Lago, Ji‐Eun Lee, Jihoon Park, Matthew P. Donnelly, Matthew F. Starost, Chengyu Liu, Jaeyul Kwon, Audrey C. Noguchi, Kai Ge et al. · 2020 · Cell Reports
  3. Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis
    Yukinari Haraoka, Yuki Akieda, Yuri Nagai, Chihiro Mogi, Tohru Ishitani · 2022 · Nature Communications
  4. Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
    Lesley Paige Ferguson, Jovylyn Gatchalian, Matthew L. McDermott, Mari Nakamura, Kendall R. Chambers, Nirakar Rajbhandari, Nikki K. Lytle, Sara Brin Rosenthal, Michael Hamilton, Sonia Albini et al. · 2023 · Nature Communications
  5. Mice Lacking the p53/p63 Target Gene Perp Are Resistant to Papilloma Development
    Michelle R. Marques, Jennifer S. Horner, Rebecca A. Ihrie, Roderick Terry Bronson, Laura Donatella Attardi · 2005 · Cancer Research
  6. Role of the p53 Family in Stabilizing the Genome and Preventing Polyploidization
    Flaminia Talos, Ute Martha Moll · 2010 · Advances in experimental medicine and biology
  7. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships
    Fiamma Mantovani, Alessandro Zannini, Alessandra Rustighi, Giannino Del Sal · 2015 · Biochimica et Biophysica Acta (BBA) - General Subjects
  8. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network
    Eleonora Mammarella, Carlotta Zampieri, Emanuele Panatta, Gerry Melino, Ivano Amelio · 2021 · Biology Direct
  9. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
    YiQing Lü, Tiffany Cho, Saptaparna Mukherjee, Carmen Florencia Suarez, Nicolás S. González Foutel, Ahmad Malik, Sébastien Martinez, Dzana Dervovic, Robin Hyunseo Oh, Ellen R. Langille et al. · 2024 · Molecular Systems Biology
  10. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice
    Amanda M. Goh, Yuezhen Xue, Marc Leushacke, Ling Li, Julin S. Wong, Poh Cheang Chiam, Siti Aishah B. Rahmat, Michael B. Mann, Karen M. Mann, Nick Barker et al. · 2015 · Oncotarget
  11. Cancer Stem Cell Marker Phenotypes Are Reversible and Functionally Homogeneous in a Preclinical Model of Pancreatic Cancer
    Joseph S. Dosch, Elizabeth K. Ziemke, Amrith Shettigar, Alnawaz Rehemtulla, Judith S. Sebolt · 2015 · Cancer Research
  12. Association of RASSF1A and p63 with Poor Recurrence-Free Survival in Node-Negative Stage I–II Non–Small Cell Lung Cancer
    Eunkyung Ko, Bo Bin Lee, Yujin Kim, Eun Ju Lee, Eun Yoon Cho, Jungho Han, Young Mog Shim, Joobae Park, Duk-Hwan Kim · 2013 · Clinical Cancer Research
  13. Mouse models of sarcomas: critical tools in our understanding of the pathobiology
    Sean M. Post · 2012 · Clinical Sarcoma Research
  14. Intestinal Dysplasia Induced by Simian Virus 40 T Antigen Is Independent of p53
    Jennifer A. Markovics, Patrick A. Carroll, Maria Teresa Sáenz Robles, Hannah Pope, Craig M. Coopersmith, James M. Pipas · 2005 · Journal of Virology
  15. Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor
    Lingyun Qin, Fei Yang, Cindy Ke Zhou, Yao Chen, Hua‐Shan Zhang, Zhengding Su · 2014 · Journal of the American Chemical Society · Retracted
  16. Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma
    Weibin Hou, Zhigang Ji · 2018 · Experimental & Molecular Medicine
  17. Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas
    Camille Jacques, Robel A. Tesfaye, Mélanie Lavaud, Steven Georges, Marc Baud’huin, François Lamoureux, Benjamin Ory · 2020 · Cells
  18. Resistance of mitochondrial p53 to dominant inhibition
    Kristina Heyne, Katrin Schmitt, Daniel Mueller, Vivienne Armbruester, P. Mestres, Klaus Roemer · 2008 · Molecular Cancer
  19. Transcriptional Regulation by Mutant p53 and Oncogenesis
    Raffaela Santoro, Sabrina Strano, Giovanni Blandino · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  20. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer
    Julie A. Barta, Kristen Pauley, Andrew V. Kossenkov, Steven B. McMahon · 2019 · Carcinogenesis
  21. CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma
    Hui Wang, Xuming Song, Yajing Wang, Yin Xuewen, Yingkuan Liang, Te Zhang, Lin Xu, Feng Jiang, Gaochao Dong · 2020 · Cell Death and Disease
  22. Induction of Apoptosis and Autophagy by Ternary Copper Complex Towards Breast Cancer Cells
    Zheng Yang Lee, Chee Hong Leong, Krystal U. Ling Lim, Christopher Chun Sing Wong, Pornwasu Pongtheerawan, Sathiavani Arikrishnan, Kian Leong Tan, Jian Sheng Loh, May Lee Low, Chee Wun How et al. · 2021 · Anti-Cancer Agents in Medicinal Chemistry
  23. Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer
    Therese Seidlitz, Tim Schmäche, Fernando Garcı́a, Joon Ho Lee, Nan Qin, Susan Kochall, Juliane Fohgrub, David Pauck, Alexander Rothe, Bon‐Kyoung Koo et al. · 2022 · EMBO Molecular Medicine
  24. Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation
    An Xu, Mo Liu, Mo-Fan Huang, Yang Zhang, Ruifeng Hu, Julian A. Gingold, Ying Liu, Dandan Zhu, Chian‐Shiu Chien, Wei‐Chen Wang et al. · 2023 · Nature Communications
  25. Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice
    Benjamin L. Johnson, Marcela d'Alincourt Salazar, Sarah Mackenzie‐Dyck, Massimo D’Apuzzo, Hung-Ping Shih, Edwin Ramos Manuel, Don J. Diamond · 2019 · PLoS ONE
  26. Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study
    María Auxiliadora Olivares‐Urbano, Carmen Griñán‐Lisón, Mercedes Zurita, Rosario Del Moral, Sandra Ríos‐Arrabal, Francisco Artacho‐Cordón, Juan Pedro Arrebola, Amanda Rocío González, Josefa León, Juan Antonio Marchal et al. · 2019 · Journal of Cellular and Molecular Medicine
  27. Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse
    Guo, Xiaofeng, Liu, Yan, Kim, Jessica L., Kim, Emily Y., Kim, Edison Q., Jansen, Alexandria, Li, Katherine, Chan, May, Keenan, Brendan T., Conejo-Garcia, Jose et al. · 2019 · PLOS ONE
  28. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma
    Shin Hamada, Tooru Shimosegawa, Keiko Taguchi, Tatsuhide Nabeshima, Masayuki P. Yamamoto, Atsushi Masamune · 2017 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  29. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder
    Norihiko Masuda, Kaoru Murakami, Yuki Kita, Akihiro Hamada, Mayumi Kamada, Yuki Teramoto, Toru Sakatani, Keiyu Matsumoto, Takeshi Sano, Ryoichi Saito et al. · 2020 · American Journal Of Pathology
  30. A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer
    Maria Grzes, Magdalena Oroń, Zuzanna Staszczak, Akanksha Jaiswar, Magdalena Nowak-Niezgoda, Dawid Walerych · 2020 · Cancers
  31. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3
    Catherine A. Vaughan, Shilpa Singh, Mark A. Subler, Jolene J. Windle, Kazushi Inoue, Elizabeth A. Fry, Raghavendra Pillappa, Steven R. Grossman, Brad E. Windle, William Andrew Yeudall et al. · 2021 · Nature Communications
  32. The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model
    John R. Jeffers, Emilia Modolo Pinto, Jerold E. Rehg, Michael R. Clay, Jinling Wang, Geoffrey A. M. Neale, Richard J. Heath, Guillermina Lozano, Enzo Lalli, Bonald Cavalcante de Figueiredo et al. · 2021 · Cancer Research
  33. Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
    Shengliang Zhang, Lanlan Zhou, Wafik S. El‐Deiry · 2022 · Molecular Cancer Research
  34. Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model
    Yulong Liang, Hongwen Gao, S-Y Lin, John A. Goss, Chunying Du, K Li · 2014 · Oncogene
  35. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo
    Elizabeth A. Slee, Barbara Benassi, Robert David Goldin, Shan Zhong, Indrika Ratnayaka, Giovanni Blandino, Xin Lü · 2010 · Proceedings of the National Academy of Sciences
  36. Cooperation between Rb and Arf in suppressing mouse retinoblastoma
    Karina L. Conkrite, Maggie Sundby, David Mu, Shizuo Mukai, David P MacPherson · 2012 · Journal of Clinical Investigation
  37. Fishing for Intestinal Cancer Models: Unraveling Gastrointestinal Homeostasis and Tumorigenesis in Zebrafish
    Ana Faro, Sylvia F. Boj, Hans C. Clevers · 2009 · Zebrafish
  38. Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium
    Kyra M. Archibald, Hagen Kulbe, Joseph Kwong, Probir Chakravarty, Jillian Temple, Tracy Chaplin, Magdalena B. Flak, Iain A. McNeish, Suha Deen, James D. Brenton et al. · 2012 · Oncogene
  39. Rab11-FIP1 mediates epithelial-mesenchymal transition and invasion in esophageal cancer
    Qiaosi Tang, Ashley Lento, Kensuke Suzuki, Gizem Efe, Tatiana A. Karakasheva, Apple Long, Véronique Giroux, Mirazul Islam, E. Paul Wileyto, Andres J. Klein–Szanto et al. · 2021 · EMBO Reports
  40. An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients
    Gurinder S. Atwal, Raúl Rabadán, Guillermina Lozano, Louise C. Strong, Mariëlle Ruijs, Marjanka K. Schmidt, Laura J. van’t Veer, Heli A. Nevanlinna, Johanna Tommiska, Kristiina Aittomäki et al. · 2008 · PLoS ONE
  41. Mutant p53 regulates Survivin to foster lung metastasis
    Qiaosi Tang, Gizem Efe, Anna M. Chiarella, Jessica C. Leung, Maoting Chen, Taiji Yamazoe, Zhenyi Su, Jason Robert Pitarresi, Jinyang Li, Mirazul Islam et al. · 2021 · Genes & Development
  42. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis
    Jinyu Tang, Ying Feng, Rork D. Kuick, Megan Green, Maranne E. Green, Naoya Sakamoto, Yuki Kurosu, Jeffry Lin, Kathleen R. Cho, Eric R. Fearon · 2019 · Laboratory Investigation
  43. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis
    Donglin Ding, Alexandra M. Blee, Jianong Zhang, Yunqian Pan, Nicole A. Becker, Louis James Maher, Rafael E. Jiménez, Liguo Wang, Haojie Huang · 2023 · Nature Communications
  44. Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish
    Joy Shijia Chua, Hoe Peng Liew, Lin Guo, David Philip Lane · 2015 · Oncogene
  45. The possible evolutionary role of tumors in the origin of new cell types
    Andrei P. Kozlov · 2009 · Medical Hypotheses
  46. Evidence for an alternate molecular progression in prostate cancer
    Ruth L. Vinall, Jane Q. Chen, Neil E. Hubbard, Shola S. Sulaimon, Ralph Devere White, Alexander D. Borowsky · 2012 · Disease Models & Mechanisms
  47. Human p53 knock-in ( hupki ) mice do not differ in liver tumor response from their counterparts with murine p53
    Maike Jaworski, Stephan Hailfinger, Albrecht Buchmann, Manfred Hergenhahn, Monica Hollstein, Carina Ittrich, Michael Schwarz · 2005 · Carcinogenesis
  48. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity
    Leixiang Yang, Tanjing Song, Qian Cheng, Lihong Chen, Jiandong Chen · 2018 · Molecular and Cellular Biology
  49. The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis
    Leah C. Young, Angela M. Keuling, Raymond L. Lai, Patrick N. Nation, Victor A. Tron, Susan E. Andrew · 2007 · Carcinogenesis
  50. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice
    T M Johnson, Laura Donatella Attardi · 2006 · Cell Death and Differentiation
  51. Conditional Knockout Mouse Models of Cancer
    Chu‐Xia Deng · 2014 · Cold Spring Harbor Protocols
  52. Disarming mutant p53 oncogenic function
    Javier E. Girardini, Carolina Marotta, Giannino Del Sal · 2013 · Pharmacological Research
  53. Drosophila p53 directs nonapoptotic programs in postmitotic tissue
    Paula Kurtz, Amanda E. Jones, Bhavana Tiwari, Nichole Link, Annika Wylie, Charles Tracy, Helmut Krämer, John Abrams · 2019 · Molecular Biology of the Cell
  54. Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA
    Guanglin Niu, Isabel Hellmuth, Tatiana Flisikowska, Hubert Pausch, Beate Rieblinger, Alexander Rinke Carrapeiro, Benjamin Schade, Brigitte Böhm, Eva Kappe, Konrad Fischer et al. · 2021 · Oncogene
  55. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
    Junjie Li, Jing Wang, Dan Su, Xiu Nie, Yueping Liu, Lianghong Teng, Junyi Pang, Huanwen Wu, Zhiyong Liang · 2021 · Gastroenterology Research and Practice
  56. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models
    Brian T. DeCant, Daniel R. Principe, Carmen E. Guerra, Marina Pasca di Magliano, Paul J. Grippo · 2014 · Frontiers in Physiology
  57. Genetically engineered mouse models for skin research: Taking the next step
    Chen Jiang, Dennis R. Roop · 2008 · Journal of Dermatological Science
  58. Lung Cancer Stem Cells, p53 Mutations and MDM2
    Venkat Sundar Gadepalli, Swati Palit Deb, Sumitra Deb, Raj Raghavendra Rao · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  59. Human pancreatic cancer progression: an anarchy among CCN-siblings
    Sushanta K. Banerjee, Gargi Maity, Inamul Haque, Arnab Ghosh, Sandipto Sarkar, Vijayalaxmi G. Gupta, Donald R. Campbell, Daniel D. Von Hoff, Snigdha Banerjee · 2016 · Journal of Cell Communication and Signaling
  60. Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
    Amanda MacDonald, Michelle Priess, Jennifer Curran, Jamey R. Guess, Victor Farutin, Ilse Oosterom, Chia Lin Chu, Edward D. Cochran, Lynn Zhang, Kristen M. Getchell et al. · 2018 · Molecular Cancer Therapeutics
  61. A clinical guide to TP53 mutations in myeloid neoplasms
    Samuel Urrutia, Terrence N. Wong, Daniel C. Link · 2025 · Blood
  62. SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes
    Katharine J. Herbert, Anthony L. Cook, Elizabeth T. Snow · 2014 · Toxicology and Applied Pharmacology
  63. Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness
    Shinjinee Sengupta, Shaikh Maryam Ghufran, Aqsa A Khan, Subhrajit Biswas, Susanta Roychoudhury · 2022 · Cancer Cell International
  64. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
    Evangelos Pavlakis, Michelle M. Neumann, Nastasja Merle, Ronja Wieboldt, Michael Wanzel, Viviane Ponath, Elke Pogge von Strandmann, Sabrina Elmshäuser, Thorsten Stiewe · 2023 · Journal of Experimental & Clinical Cancer Research
  65. Sleeping Beauty transposon mutagenesis identified genes and pathways involved in inflammation-associated colon tumor development
    Kana Shimomura, Naoko Hattori, Naoko Iida, Yukari Muranaka, Kotomi Sato, Yuichi Shiraishi, Yasuhito Arai, Natsuko Hama, Tatsuhiro Shibata, Daichi Narushima et al. · 2023 · Nature Communications
  66. RNF125 is a Ubiquitin-Protein Ligase that Promotes p53 Degradation
    Liuzhong Yang, Bing Zhou, Xiaorui Li, Zhihong Lu, Weiwei Li, Xiaoqing Huo, Zhanhui Miao · 2015 · Cellular Physiology and Biochemistry
  67. P53 at the start of the 21st century: lessons from elephants
    Sue Haupt, Ygal Haupt · 2017 · F1000Research
  68. Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant
    Wenshu Li, Longyuan Li, Huan Yang, Chenxi Shi, Zhe Lei, Lingchuan Guo, Yuhong Wang · 2024 · Frontiers in Bioscience-Landmark
  69. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres
    Oumar Samassékou, Nathalie Bastien, Daniel Lichtensztejn, Ju Yan, Sabine Mai, Régen Drouin · 2014 · Genes Chromosomes and Cancer
  70. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
    Toshihiro Morita, Yuzo Kodama, Masahiro Shiokawa, Katsutoshi Kuriyama, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Tomoaki Matsumori, Nobuyuki Kakiuchi, Teruko Tomono et al. · 2020 · Cancer Research
  71. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines
    Laura Hartmann, Philipp Schröter, Wolfram Osen, Daniel Baumann, Rienk Offringa, Mahmoud Moustafa, Rainer D. Will, Jürgen Debus, Stephan Brons, Stefan Rieken et al. · 2020 · Scientific Reports
  72. Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution
    Nicole M. Sodir, Luca Pellegrinet, Roderik M. Kortlever, Tania Campos, Yong-Won Kwon, Shinseog Kim, Daniel A. Garcia, Alessandra Perfetto, Panayiotis Anastasiou, Lamorna Brown Swigart et al. · 2022 · Nature Communications
  73. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
    Anne Huber, Amr H. Allam, Christine Dijkstra, Stefan Thiem, Jennifer Huynh, Ashleigh R. Poh, Joshua Konecnik, Saumya P. Jacob, Rita A. Busuttil, Yang Liao et al. · 2024 · Cell Reports
  74. ShaPINg Cell Fate Upon DNA Damage: Role of Pin1 Isomerase in DNA Damage-Induced Cell Death and Repair
    Tilman Polonio-Vallon, Daniel Krüger, Thomas G. Hofmann · 2014 · Frontiers in Oncology
  75. p53 Family: Therapeutic Targets in Neuroblastoma
    Jennifer K. Wolter, Paola Angelini, Meredith S. Irwin · 2010 · Future Oncology
  76. P53 Gene Mutation Increases Progastrin Dependent Colonic Proliferation and Colon Cancer Formation in Mice
    Vigneshwaran Ramanathan, Guangchun Jin, Christoph Benedikt Westphalen, Ashley D. Whelan, Alexander N. Dubeykovskiy, Shigeo Takaishi, Timothy Cragin Wang · 2012 · Cancer Investigation
  77. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
    Sara Donzelli, Francesca Biagioni, Francesca Fausti, Sabrina Strano, Giulia Fontemaggi, Giovanni Blandino · 2008 · Current Genomics
  78. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death
    Mizuyo Nakamura, Hirokazu Sugimoto, Takehiko Ogata, Kiriko Hiraoka, Hiroyuki Yoda, Meijie Sang, Meijie Sang, Yuyan Zhu, Meng Yu, Osamu Shimozato et al. · 2016 · Oncogenesis
  79. Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface
    Subbulakshmi Karthikeyan, Daniel D. Lantvit, Dam Hee Chae, Joanna E. Burdette · 2016 · Oncotarget
  80. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells
    Catherine A. Vaughan, Shilpa Singh, Steven R. Grossman, Brad E. Windle, Swati Palit Deb, Sumitra Deb · 2017 · Molecular Oncology
  81. A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation
    Marina Kazantseva, Sunali Y. Mehta, Ramona A. Eiholzer, Noelyn Anne Hung, Anna K. Wiles, Tania L. Slatter, Antony W. Braithwaite · 2018 · Mammalian Genome
  82. Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition
    Arthur Brannon, Donovan Drouillard, Nina G. Steele, Shadae Schoettle, Ethan V. Abel, Howard C. Crawford, Marina Pasca di Magliano · 2020 · Scientific Reports
  83. Mouse embryonic stem cells with a multi-integrase mouse artificial chromosome for transchromosomic mouse generation
    Yuki Yoshimura, Kazuomi Nakamura, Takeshi Endo, Naoyo Kajitani, Kanako Kazuki, Yasuhiro Kazuki, Hiroyuki Kugoh, Mitsuo Oshimura, Tetsuya Ohbayashi · 2015 · Transgenic Research
  84. Development of mouse models of angiosarcoma driven by p53
    Donald McGovern Salter, Meredyth Griffin, Morwenna Muir, Katy Teo, Jayne Culley, James R. Smith, Laura Gómez-Cuadrado, Kylie P. Matchett, Andrew H. Sims, Larry Hayward et al. · 2019 · Disease Models & Mechanisms
  85. Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression
    Tania Pannellini, Michela Spadaro, Emma Di Carlo, Elena Ambrosino, Manuela Iezzi, Augusto Roca De Amici, Pier‐Luigi Lollini, Guido Forni, Federica Cavallo, Piero Musiani · 2006 · The Journal of Immunology
  86. Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy
    Kevin B. Spurgers, Nikhil S. Chari, Nicole L. Bohnenstiehl, Timothy J. McDonnell · 2006 · Cell Death and Differentiation
  87. Mutant p53 Gain of Function: Why Many See It, Why Some Do Not
    Guillermina Lozano, Carol L. Prives, Kanaga Sabapathy · 2025 · Cancer Discovery
  88. Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth
    Jieqiong Wang, Yajie Chen, Canhua Huang, Qian Hao, Shelya X. Zeng, Sara Omari, Yu Zhang, Xiang Yu Zhou, Hua Lu · 2021 · Cancer Research
  89. Mechanistic roles of mutant p53 governing lipid metabolism
    Ryan M. Loughran, Brooke M. Emerling · 2021 · Advances in Biological Regulation
  90. Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice
    Stephanie Grabow, Paul Waring, Lina Happo, Michele Cook, Kylie D. Mason, Priscilla N. Kelly, Andreas Strasser · 2011 · Cell Death and Differentiation
  91. Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3β and causes increased cell migration
    Nico Münnich, Simon Wernhart, Christer Högstrand, Uwe Schlomann, Christopher Nimsky, Jörg Walter Bartsch · 2016 · BioMetals
  92. Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity
    Valentina A. Schmidt, Rachana Nagar, Luis A. Martinez · 2017 · International Journal of Molecular Sciences
  93. Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers
    So‐Young Park, Ah-Young Oh, Jung-Hyun Cho, Min-Ho Yoon, Tae-Gyun Woo, So‐mi Kang, Ho‐Young Lee, Youn-Jin Jung, Bum-Joon Park · 2018 · Molecular Cancer Research
  94. S100A4 interacts with mutant p53 and affects gastric cancer MKN1 cell autophagy and differentiation
    Wei Shen, DANQI CHEN, Shanshan Liu, Lisha Chen, Aiwen Yu, HAO FU, Xiuju Sun · 2015 · International Journal of Oncology
  95. Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma
    Jingmin Shu, Lihua Li, Anne E. Sarver, Emily A. Pope, Jyotika Varshney, Venugopal Thayanithy, Logan G. Spector, David A. Largaespada, Clifford J. Steer, Subbaya Subramanian · 2016 · Oncotarget
  96. The DNA resection protein CtIP promotes mammary tumorigenesis
    Colleen R. Reczek, Reena Shakya, Yana Miteva, Matthias J. Szabolcs, Thomas Ludwig, Richard J. Baer · 2016 · Oncotarget
  97. Nuclear Factor Erythroid 2–Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression
    Ryotaro Matsumoto, Shin Hamada, Yu Tanaka, Keiko Taguchi, Masayuki P. Yamamoto, Atsushi Masamune · 2021 · Journal of Pharmacology and Experimental Therapeutics
  98. Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function
    Jun A. Takahashi, Takafumi Suzuki, Miu Sato, Shuji Nitta, Nahoko Yaguchi, Tatsuki Muta, Kouhei Tsuchida, Hiromi Suda, Masanobu Morita, Shin Hamada et al. · 2024 · Cell Reports
  99. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice
    Wenrui Duan, Li Gao, David Jin, Gregory A. Otterson, Miguel Angel Villalona-Calero · 2007 · Transgenic Research
  100. Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts
    Annette M. Krais, Karl–Rudolf Muehlbauer, Jill E. Kucab, Helena Chinbuah, Michael G. Cornelius, Quan-Xiang Wei, Monica Hollstein, David H. Phillips, Volker Manfred Arlt, Heinz H. Schmeiser · 2014 · Toxicology in Vitro